Interpatient variability: Genetic predisposition and other genetic factors

Journal of Clinical Pharmacology

Volumn 37, Issue 7, 1997, Pages 635-648

  West, William L ^a,c   Knight, Enid M ^a   Pradhan, Sikta ^b   Hinds, Tanya S ^a  

^a HOWARD UNIVERSITY   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; COCAINE; CYTOCHROME P450; DEBRISOQUINE; DECONGESTIVE AGENT; DICOUMAROL; DOPAMINE RECEPTOR STIMULATING AGENT; ENCAINIDE; ERYTHROMYCIN; ESTROGEN; FLUOXETINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; KETOCONAZOLE; MEPHENYTOIN; NEUROLEPTIC AGENT; OPIATE AGONIST; PHENAZONE; PHENOBARBITAL; PHENYTOIN; QUINIDINE; RIFAMPICIN; SPARTEINE; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

ARTICLE; DEMETHYLATION; DRUG DISPOSITION; DRUG HYDROLYSIS; DRUG HYDROXYLATION; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME POLYMORPHISM; GENETIC VARIABILITY; HUMAN; METHYLATION;

EID: 0030769413     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04347.x     Document Type: Article

References (76)

1. Kalow W: Pharmacogenetics and anthropology. In: Lemberger L, Reidenberg MM (eds.): Proceedings of the Second World Conference on Clinical Pharmacology and Therapeutics. Washington, DC: American Society for Pharmacology and Experimental Therapeutics, 1984;264.
2. Kalow W: The metabolism of xenobiotics in different populations. Can J Physiol Pharmacol 1982;60:1.
3. Nebert DW, Adesnick M, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, et al: The P-450 gene superfamily: recommended nomenclature. DNA 1987;6:1-11.
4. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
5. Edwards JH: Familial predisposition in man. Br Med Bull 1969;25:58.
6. O'Reilly RA: The second reported kindred with hereditary resistance to oral anticoagulant drugs. N Engl J Med 1970;282:1448-1451.
7. O'Reilly RA, Aggler PM: Determination of the response to oral anticoagulant drugs in man. Pharmacol Rev 1970;22:35.
8. O'Reilly RA: Vitamin K in hereditary resistance to oral anticoagulant drugs. Am J Physiol 1971;221:1327.
9. Gallop PM, Lian JB, Hauscha PV: Carhoxylated calcium binding proteins and vitamin K. N Engl J Med 1980;302:1460-1466.
10. Kalow W, Genest K: A method for the detection of atypical forms of human serum cholinesterase: determination of dibucaine numbers. Can J Biochem Physiol 1957;35:339-346.
11. Clark SW, Glaukbiger GA, La Du BN: Properties of plasma cholinesterase variants. Ann N Y Acad Sci 1968; 151:710-722.
12. Wedlund PJ, Asianian WS, McAllister CB, Wilkinson GR, Branch RA: Mephenytoin hydroxylation deficiency in Caucasians: frequency of new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984;36:773-780.
13. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou HH, Zhou BJ, et al: Metoprolol and mephenytoin oxidation polymorphism in far eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989;46:198-207.
14. Inaba T, George LF, Arias TD: Mephenytoin hydroxylation in the Cuna Amerindians of Panama. Br J Clin Pharmacol 1988; 25:75-79.
15. Blum M, Grant DM, McBride W, Heim M, Meyer UA: Human arylamine n-acetyl transferase genes: isolation, chromosomal location and function expression. DNA Cell Biol 1990;9:193-203.
16. Grant DM, Blum M, Beer M, Meyer UA: Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isoenzymes and expressed products of two cloned genes. Mol Pharmacol 1991;39:184-191.
17. Turgeon DK, Normolle DP, Leichman AB, Annesley TM, Smith DE, Watkins PB: Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther 1992;52:471-478.
18. Johansson I, Yue QY, Dahl ML, Heim M, Sawe J, Bertilsson L, et al: Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Br J Clin Pharmacol 1991;40:553-556.
19. Heim M, Meyer UA: Genotyping of poor metabolizers of debrisoquine by allele-speciflc PCR amplification. Lancet 1990; 336:529-532.
20. Nelson DR, Karnataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, et al: The P-450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature. DNA Cell Biol 1993;12:1-51.
21. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer U: Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991;10:545-558.
22. Carey EL, Duff HJ, Roden DR, Prim RK, Wilkinson GR, Wang T, et al: Encainide and its metabolites: comparative effects in man on ventricular arrhythmia and electrocardiographic intervals. J Clin Invest 1984;73:539-547.
23. Law MR, Hetzel MR, Idle JR: Debrisoquine metabolism and genetic predisposition to lung cancer. Br J Cancer 1989;59:686-687.
24. Agundez JAG, Martinez C, Ladero JM, Ledesma MC, Ramos JM, Martin R, et al: Pharmacokinetics and drug disposition: debrisoquine oxidation genotype and susceptibility to lung cancer. Clin Pharmacol Ther 1994;55:10-14.
25. Kerry NL, Somogyi AA, Bochner F, Mikus G: The role of CYP in primary and secondary oxidative metabolism of dextromethorphan in vitro studies using human liver microsomes. Br J Clin Pharmacol 1994;38:243-248.
26. Mikus G, Bochner F, Eichelbaum M, Horak P, Somogyi AA, Spector S: Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism. J Pharmacol Exp Ther 1994;268:546-551.
27. Sindrup SH, Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF: Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? Pain 1993;53:335-339.
28. Fleming CM, Branch RA, Wilkinson GR, Guengerich FP: Human liver microsomal N-hydroxylation of dapsone by cytochrome P-450 3A4. Mol Pharmacol 1992;41:975-980.
29. Wu D, Otton SV, Sproule BA, Busto U, Inaba T, Kalow W, Sellers EM: Inhibition of human cytochomes P-450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol 1993;35:30-34.
30. Sindrup SH, Arendt-Nielsen L, Brosen K, Bjerring P, Angelo HR, Eriksen B: The effect of quinidine on the analgesic effect of codeine. Eur J Clin Pharmacol 1992;42:587-591.
31. Herbert MF, Roberts JP, Prueksaritanont T, Benet LZ: Bioavailability of cyclosporine with concomitant rifampin administration is marked less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-457.
32. Troy SM, Parker VD, Fruncillo RJ, Chiang ST: The pharmacokinetics of venlafaxine when given in a twice daily regimen. J Clin Pharmacol 1995;35:404-409.
33. Brosen K, Skjelbo E: Fluoxetine and norfluoxetine are potent inhibitors of P4502D6: the source of the sparteine/debrisoquine oxidative polymorphism. Br J Clin Pharmacol 1991;32:136-137.
34. Eichelbaum M, Gross AS: The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. Pharmacol Ther 1990;46:377-394.
35. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-598.
36. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-15422.
37. Hughes HB, Biehl JP, Jones AP, Schmidt LH: Metabolism of isoniazid in man as related to the occurrence of peripheral isoniazid neuritis. Am Rev Respir Dis 1954;70:266.
38. Hickman D, Sim E: N-acetyl transferase polymorphism comparison of phenotype and genotype in humans. Biochem Pharmacol 1991;42:1007-1014.
39. Ohsako S, Deguchi T: Cloning and expression of cDNA for polymorphic and monomorphic arylamine n-acetyltransferases from human liver. J Biol Chem 1990;285:4630-4634.
40. Baer AN, Woosley RL, Pincus T: Further evidence for the lack of association between acetylator phenotype and systemic lupus erythematosus. Arthritis Rheum 1986;29:508-514.
41. Grant DM, Morike K, Eichelbaum M, Meyer UA: Acetylation pharmacogenetics: the slow acetylator phenotype is caused by decreased or absent arylamine n-acetyl transferase in human liver. J Clin Invest 1990;85:968-972.
42. Deguchi T: Sequences and expression of alleles of polymorphic arylamine n-acetyl transferase of human liver. J Biol Chem 1992;267:18140-18147.
43. May DG, Porter J, Wilkinson GR, Branch RA: Frequency distribution of dapsone N-hydroxylase, a putative probe for P450 3A4 activity, in a white population. Clin Pharmacol Ther 1994; 55:492-500.
44. Axelrod J, Weinshilboum R: Catecholamines. N Engl J Med 1972;287:237-242.
45. Weinshilboum RM: Human pharmacogenetics of methyl conjugation. Fed Proc 1984;43:2303.
46. Nazar-Stewart V, Motulsky AG, Eaton DL, White E, Hornung SK, Leng ZT, et al: The glutathione S-transferase mu polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res 1993;53(suppl 10):2313-2318.
47. Nebert DW: Birth defects and the potential role of genetic differences in drug metabolism. Birth Defects 1981;XVII:51-70.
48. Weinshilboum RM, Raymond FA: Inheritance of low erythrocyte catechol-O-methyl transferase activity in man. Am J Hum Genet 1977;29:125-135.
49. Weinshilboum RM, Sladek S, Klumpp S: Human erythrocyte thiol methyl transferase: radiochemical micro assay and biochemical properties. Clin Chim Acta 1979;97:59.
50. Weinshilboum RM, Raymond FA, Elveback LR, Weidman WH: Correlation of erythrocyte catechol-O-methyl-transferase activity between siblings. Nature 1974;252:490-491.
51. Gershon ES, Jonas WZ: Erythrocyte soluble catechol-O-methyl transferase activity in primary affective disorder. Arch Gen Psychiatry 1975;32:1351.
52. Spielman RS, Weinshilboum RM: Genetics of red cell COMT activity: analysis of thermal stability and family data. Am J Med Genet 1981;10:279-289.
53. Reilly DK, Rivera-Calimlin L, Van Dyke D: Catechol-O-methyl transferase activity: a determination of levodopa response. Clin Pharmacol Ther 1980;28:278-288.
54. Conolly ME, Davies DS, Dollery CT: Metabolism of isoprenaline in dog and man. Br J Pharmacol 1972;46:458-472.
55. Pacifici GM, Santerini S, Giuliana L, Rane A: Thiol methyl transferase in humans: development and tissue distribution. Dev Pharmacol Ther 1994;17:8-23.
56. McLeod HL, Lin JS, Scott PE, Piu CH, Evans WE: Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994;55:15-20.
57. Lee EJD, Kalow W. Thiopurine s-methyltransferase activity in Chinese population. Clin Pharmacol Ther 1993;54:28-33.
58. Bremer J, Greenberg DM: Enzymatic methylation of foreign sulfhydryl compounds. Biochim Biophys Acta 1961;46:217.
59. Beckett GJ, Howie AF, Hume R, Matharoo B, Hiley C, Jones P, Strange RC: Human glutathione s-transferases: radioimmunoassay studies on the expression of alpha-, mu-and pi-class isoenzymes in developing lung and kidney. Biochim Biophys Acta 1990; 1036:176-182.
60. Liu YH, Taylor J, Linko P, Lucier GW, Thompson CL: Glutathione S-transferase mu in human lymphocyte and liver: role in the modulating formation of carcinogen-derived DNA adducts. Carcinogenesis 1991;12:2269-2275.
61. 1-0 phenotype in patients with adenocarcinoma. Carcinogenesis 1991;2:25-28.
62. Fryer AA, Zhao L, Alldersea J, Boggild MD, Perrett CW, Clayton RN, et al: The glutathione S-transferases: polymerase chain reaction studies on the frequency of the GSTM1 0 genotype in patients with pituitary adenomas. Carcinogenesis 1993;14:563-566.
63. Warholm M, Guthenberg C, Mannervick B: Molecular and catalytic properties of glutathione transferase mu from human liver: an enzyme efficiently conjugating epoxides. Biochemistry 1983;22:3610-3617.
64. Nebert DW, Puga A, Vasilou V: The role of the AH receptor and the dioxin-inducible gene battery in toxicity, cancer, and signal transduction. Ann N Y Acad Sci 1993;685:624-640.
65. 3H]GBR-12935 binding proteins. Arch Biochem Biophys 1990;276:424-432.
66. Motulsky AG, Yoshida A, Stamatoyannopoulos G: Variants of glucose-6-phosphate dehydrogenase. Ann N Y Acad Sci 1971; 179:636-643.
67. Chan TK, Todd D, Tso SC: Drug-induced hemolysis in glucose-6-phosphate dehydrogenase deficiency. BMJ 1976;2:1227-1229.
68. Cohen RJ, Sachs JR, Wicher DJ, Conrod ME: Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam. N Engl J Med 1968;279:1127-1131.
69. Britt BA: Malignant hyperthermia. Clin Anesth 1975;11:61.
70. Kenna CJ, Knight TL, VanPelt FNAM: Immunity to halothane metabolite-modified proteins in halothane hepatitis. Ann N Y Acad Sci 1993;685:646-661.
71. Catteau A, Bechtel YC, Poisson N, Bechtel PR: A population and family study of CYP1A2 using caffeine urinary metabolites. Eur J Clin Pharmacol 1995;47:423-430.
72. Hiratsuka A, Chu TY, Distefeno EW, Lin LY, Schmitz DA, Cho AK: In activation of constitutive hepatic cytochrome P450 by phencyclidine in the rat. Drug Metab Dispos 1995;23:201-206.
73. Shelnutt SR, Badger TM, Owens SM: Phencycline metabolite irreversible binding in the rat: gonadal steroid regulation and CYP2C11. J Pharmacol Exp Ther 1996;277:292-298.
74. Nakajima M, Yamaoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, et al: Characterization of CYP2A6 involved in 3′-hydroxylation of continine in human liver microsomes. J Pharmacol Exp Ther 1966;277:1010-1015.
75. Wennberg RP, Yin J, Miller M, Maynar A: Fetal cocaine exposure and neonatal bilirubinemia. J Pediatr 1994;124:613-616.
76. Pellinen P, Honkakoski P, Stenback F, Niemitz M, Alhaua E, Pelkonen O, et al: Cocaine N-demethylation and the metabolism-related hepatotoxicity can be inhibited by cytochrome P450 3A inhibitors. Eur J Pharmacol 1994;270:35-43.